About the Company
Mateon Therapeutics is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTTs include vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA approved and widely used in cancer treatment. These 2 approaches (VDAs and AAs) have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by combining these 2 complementary approaches. When utilized this way, VDAs disrupt existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
We are committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors
SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the Markey Cancer Center at the University...
Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., April 18, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced interim data from its first scheduled analysis of...